Epidemiology and survival of hepatocellular carcinoma in Turkey: Outcome of multicenter study

Japanese Journal of Clinical Oncology

Volumn 38, Issue 10, 2008, Pages 683-688

  Alacacioglu, Ahmet ^a   Somali, Isil ^a   Simsek, Ilkay ^a   Astarcioglu, Ibrahim ^a   Ozkan, Metin ^b   Camci, Cemalettin ^c   Alkis, Necati ^d   Karaoglu, Aziz ^e   Tarhan, Oktay ^a   Unek, Tugba ^a   Yilmaz, Ugur ^a  

^a DOKUZ EYLUL UNIVERSITY   (Turkey)

^b ERCIYES UNIVERSITY   (Turkey)

^c GAZIANTEP UNIVERSITY   (Turkey)

^d ANKARA ONCOLOGY HOSPITAL   (Turkey)

^e FIRAT UNIVERSITY   (Turkey)

Author keywords

HCC; Hepatocellular cancer; Prognosis; Turkey

Indexed keywords

ALPHA FETOPROTEIN; ANTINEOPLASTIC AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER HORMONE THERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER METASTASIS; LIVER NODULE; LIVER TRANSPLANTATION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OVERALL SURVIVAL; PALLIATIVE THERAPY; POPULATION RESEARCH; PROGNOSIS; TREATMENT OUTCOME; TURKEY (REPUBLIC);

ADOLESCENT; ADULT; AGED; ALPHA-FETOPROTEINS; CARCINOMA, HEPATOCELLULAR; FEMALE; FOLLOW-UP STUDIES; HEPACIVIRUS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; INCIDENCE; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RISK FACTORS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; TURKEY;

EID: 54949122971     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyn082     Document Type: Article

References (12)

1. Monto A, Wright TL. The epidemiology and prevention of hepatocellular carcinoma. Semin Oncol 2001;28:441-9.
2. Sewart BW, Kleihues P. World Cancer Report. IARC Pres: Lyon 2003, 11-9.
3. Uzunalimog. lu O, Yurdaydin C, Cetinkaya H, Bozkaya H, Sahin T, Colakog.lu S, et al. Risk factors for hepatocellular carcinoma in Turkey. Dig Dis Sci 2001;46:1022-8.
4. Borzio M, Colloredo G, Pioltelli P, Quagliuolo M. Epidemiology and outcome of hepatocellular carcinoma in Lombardy. Dig Liver Dis 2007;39:1011-7.
5. Markovic S, Gadzijev E, Stabuc B, Croce LS, Masutti F, Surlan M, et al. Treatment options in Western hepatocellular carcinoma: A prospective study of 224 patients. J Hepatol 1998;29:650-9.
6. Stroffolini T, Andreone P, Andriulli A, Ascione A, Craxi A, Chiaramonte M, et al. Characteristics of hepatocellular carcinoma in Italy. J Hepatol 1998;29:944-52.
7. Sakar B, Ustuner Z, Karagol H, Aksu G, Camlica H, Aykan NF. Prognostic features and survival of inoperable hepatocellular carcinoma in Turkish patients with cirrhosis. Am J Clin Oncol 2004;27:489-93.
8. Dohmen K, Shigematsu H, Irie K, Ishibashi H. Longer survival in female than male with hepatocellular carcinoma. J Gastroenterol Hepatol 2003;18:267-72.
9. Wang BE, Ma WM, Sulaiman A, Noer S, Sumoharjo S, Sumarsidi D, et al. Demographic, clinical, and virological characteristics of hepatocellular carcinoma in Asia: Survey of 414 patients from four countries. J Med Virol 2002;67:394-400.
10. Fong Y, Sun RL, Jarnagin W, Blumgart LH. An analysis of 412 cases of hepatocellular carcinoma at a Western center. Ann Surg 1999;229:790-800.
11. Purtilo DT, Kersey JH, Hallgren HM, Fox KR, Yunis EJ. Alpha-fetoprotein: diagnostic and prognostic use in patients with hepatomas. Am J Clin Pathol 1973;59:295-9.
12. Stuart KE, Anand AJ, Jenkins RL. Hepatocellular carcinoma in the United States. Prognostic features, treatment outcome, and survival. Cancer 1996;77:2217-22.